Endocrine, Metabolic and Immune Disorders - Drug Targets
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 2.0 | Q3 | 30.3% | 0.552 | Q3 | 64.7% |
| 2024 | 2.0 | Q3 | 34.6% | 0.535 | Q3 | 64.5% |
| 2023 | 2.0 | Q3 | 39.5% | 0.495 | Q3 | 64.6% |
| 2022 | 1.9 | Q4 | 29.9% | 0.427 | Q3 | 61.2% |
| 2021 | 2.4 | Q4 | 42.2% | 0.490 | Q3 | 66.5% |
| 2020 | — | — | 0.518 | Q3 | 67.2% | |
| 2019 | — | — | 0.465 | Q3 | 65.3% | |
| 2018 | — | — | 0.656 | Q3 | 73.2% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1871-5303
ISSN
2212-3873
country
AEcoverage
2006-2026